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Abstract
Background: The prevalence of breast cancer in developed countries has steadily risen over recent decades.
Immediate and long-term health needs of patients, including preventive care and screening services, are receiving
increasing attention. A question still unresolved is whether breast cancer survivors should receive mammographic
surveillance in the clinical or screening setting and, thus, whether they should be excluded from, or invited to,
organised mammography screening programmes. The objective of this article is to discuss the many contradictory
aspects of this matter.
Discussion: Problems with mammographic surveillance of breast cancer survivors include: weak evidence of a
reduction in mortality; lack of evidence in favour of one setting or the other; lack of evidence-based guidelines for
the frequency and duration of surveillance; disproportionate emphasis placed on the first few years post-treatment,
probably dictated by surgical and oncological priorities; a variety of screening policies, as these women are
permanently or temporarily or partially excluded from many - but not all - organised screening programmes
worldwide; an even greater disparity in follow-up protocols used in the clinical setting; a paucity of data on
compliance to mammographic surveillance in both settings; and a difficulty in coordinating the roles of health care
providers. In the future, the use of mammography in breast cancer survivors will be influenced by the inclusion of
women aged > 69 years in organised screening programmes and the implementation of multidisciplinary breast
units, and will probably be investigated by research activities on individual risk assessment and risk-tailored
screening. In the interim, current problems can be partially alleviated with some technical solutions in screening
data recording, patient flows, and care coordination.
Summary: Mammographic surveillance of breast cancer survivors is situated at the crossroads of numerous
different specialist areas of breast cancer control and management. The solutions for current problems probably lie
in some important modifications in the conventional screening procedure that are underway or under study. These
developments appear to be directed towards a partial modification of the screening rationale, with an adaptation
to meet the diversified breast care needs of women. The complexity of the matter constitutes a call to action for
several entities to eliminate the barriers to effective research in this field.
Background
The prevalence of breast cancer (BC) in developed
countries has steadily increased over recent decades due
to improvements in detection and treatment of the dis-
ease. The immediate and long-term health needs of
patients are receiving increasing attention. This is also
the case for preventive care and screening services.
The subject of this article is the unresolved question
of whether patients treated for BC should receive mam-
mographic surveillance in the clinical or screening set-
ting and, thus, whether they should be excluded from,
or invited to, organised mammography screening pro-
grammes for the general female population. Up until
recently this question was seldom raised [1,2], but with
the increasing diffusion of screening, which has been
and continues to be a major factor for the increase in
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careful and thorough consideration.
The many correlates of this problem should be placed
in the wider context of cancer survivorship research.
This area of translational research, which covers a broad
range of topics including preventive measures and
screening for patients with a history of cancer, is grow-
ing exponentially and is expected to translate into new
evidence-based health care models and programmes.
The development of rational approaches to continued
breast surveillance is a key element of breast cancer sur-
vivorship agenda.
The problem of who should be responsible for the
mammographic surveillance of BC survivors involves
several specific points of interest. First, it is related to
some emerging research subjects in the area of BC
screening, such as the idea of risk-tailored screening.
Secondly, and from a larger perspective, establishing
whether women with a history of BC should be
excluded from organised screening programmes is cor-
related with numerous aspects of BC control and man-
agement. Due to this multifaceted profile, the provision
of mammographic surveillance for BC survivors raises
wider questions concerning the incorporation of screen-
ing into primary care services and the interaction
between public and personal health services.
The objective of this article is to discuss the many and
contradictory aspects of this matter and the possible
solutions. The basis for the discussion is an international
overview of screening guidelines and practices for BC
survivors. The work is directed at health policy makers,
health managers, screening authorities, and primary care
physicians. However, given the (problematic) interrela-
tionship between mammographic surveillance and clini-
cal follow-up for BC, it might also be of interest to
oncologists and other hospital specialists. The article
specifically addresses population-based, organised mam-
mography screening programmes (with active call/recall
service), as implemented in public, tax-financed health
care systems. However, some of the information
reported here comes from private insurance-based
health care systems.
T h ep o i n t sd e a l tw i t hi nt h ea r t i c l ea r et h ef o l l o w i n g :
the size of the problem, including the prevalence of BC
and the risk of ipsilateral relapse and new contralateral
cancer; the benefit of mammographic surveillance; the
published guidelines for its frequency and duration; the
strategies currently being used in organized screening
programmes and in the clinical setting; the current
levels of compliance with mammographic surveillance in
either setting; considerations that may contribute to the
rationale behind the decision-making on the provision
of the service; the current challenges and potential
developments that may be expected in the future; and
the practical solutions that can be implemented to
improve the situation in the short term.
Discussion
Size of the problem
Prevalence of BC
To calculate the complete prevalence of BC and to iden-
tify all prevalent patients, a long history of cancer regis-
tration and follow-up for vital status is needed. In the
great majority of countries and regional areas with orga-
nised screening programmes, this requirement is not or
only partially met. An alternative approach is to use sta-
tistical models such as those based on equations that
relate mortality and prevalence to incidence and survival
probabilities. Observed and estimated data provide a
fairly consistent picture of current prevalence of BC
among women living in the western world. In the Uni-
ted Kingdom [3], the Netherlands [4], Italy [5], the Uni-
ted States [6], and Australia [7], at different points in
time between 2000 and 2009, the prevalence rate was
approximately 2-2.5% around the age of 50 years and 4-
6% around the age of 70 years. Over the past few dec-
ades, a steady increase has been observed. In the United
States, for example, the rate has been projected to
increase by 40% between 2005 and 2015.
Risk of ipsilateral relapse and new contralateral cancer
The incidence of ipsilateral relapse after breast-conser-
ving surgery and radiotherapy is in the range of 0.5-1%
per year [8-10]. This rate remains constant over time
and, thus, the cumulative risk increases progressively,
even after 15 years [9]. According to some observations
[11], most ipsilateral relapses occur in the first 3 to 5
years. However, this is the case for true local recur-
rences alone, which follow the same decreasing time
trend as distant metastases. The trend of new cancers in
other areas of the treated breast is the opposite, as is
that of new contralateral cancers. As a consequence, the
pooled incidence of locoregional relapse in either breast
remains constant for over 15 years at 1-1.5% per year
[11,12]. By implication, the total cumulative risk
increases with time, and the majority of relapses occur
more than 3 years after treatment [12].
Among women aged above 50 years, a personal his-
tory of in situ or invasive BC conveys a risk of second
contralateral invasive cancer of 1.5-1.75 relative to
women with a negative history. This is equivalent to
saying that the risk of second contralateral BC is greater
than the familial risk of primary BC [13].
Effectiveness of breast surveillance
General evidence of effectiveness
The evidence that mammographic surveillance for early
detection of ipsilateral breast relapse or new contralat-
eral cancer reduces the risk of death among BC
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mized studies have been conducted, and observational
studies have often been hampered by small sample size
and low quality of design [14]. Their results have sug-
gested that regular annual or biennial mammography
is associated with a mortality reduction of varying
magnitude [15,16] or a long-term survival benefit inde-
pendent of lead time [17]. A recent review concluded
that there is evidence of a potential benefit for asymp-
tomatic second BCs compared with symptomatic ones
in various surveillance strategies that include mammo-
graphy [10].
The value of routine clinical examination in detecting
a relapse in the ipsilateral breast or axilla or a new con-
tralateral cancer is not certain. Patients with clinically
detected ipsilateral breast relapse have a poorer survival
than those whose relapse is detected by mammography
or breast self-examination. Moreover, the proportion of
relapses detected on routine clinical examination has
decreased over time, from 45% according to reports
published before 2000 to 15% according to more recent
data. In other words, the contribution of mammography
shows increasing importance because of technical
improvements and quality assurance [18]. As a conse-
quence, the question is not - or not just - whether clini-
cal examination should complement mammography, but
whether the image quality of mammograms is suffi-
ciently high to permit the omission of clinical
examination.
Breast self-examination continues to have a role in the
follow-up of BC patients. The proportion of relapses
detected by patients themselves is still about 35%. How-
ever, breast self-examination detects more ipsilateral
relapses than contralateral relapses, which suggests a
lack of patient awareness that the risk increase applies
to both breasts [18].
There are no studies showing treatment or survival
b e n e f i tf r o ma ne a r l i e rd e tection of asymptomatic
relapse of BC using magnetic resonance imaging [19].
Similarly, there are insufficient data to support the rou-
tine use of breast ultrasound in post-treatment surveil-
lance [20].
Evidence of effectiveness in different settings
Central to the present discussion is the lack of evidence
that the effect of regular mammographic surveillance
varies between the clinical and the screening setting. It
has never been demonstrated that BC survivors cannot
be screened successfully in an organised screening pro-
gramme [1]. Moreover, there are no studies showing
that the provision of mammography at intervals of less
than 12 months is more effective than at 1- or 2-year
intervals. It has been proposed that studies addressing
t h i si s s u eb eb a s e do no r g a n i sed screening programmes
[10].
International comparison of breast surveillance guidelines
and practices
Surveillance guidelines
Due to the lack of evidence-based data on the most
appropriate protocols for breast surveillance of BC
patients, published practice guidelines give somewhat
conflicting information. No consensus exists about how
frequently patients should undergo mammography and
clinical breast examination (if any), for how long they
should be seen at short intervals, and whether or when
it is appropriate for them to return to normal screening
[2,10,21,22].
For example, the United Kingdom NHS National
Institute for Health and Clinical Excellence guidelines of
2009 recommend that patients with early BC, including
ductal in situ carcinoma, be offered annual mammogra-
phy until they enter the national screening programme.
Patients who are already eligible for screening should
have annual mammography for 5 years. For patients
who reach the screening age as well as those who com-
plete 5 years of annual mammographic surveillance, it is
recommended that the screening frequency be stratified
according to the patient risk category [20].
The British Association of Surgical Oncology recom-
mends that patients be followed-up for 5 years, although
this period may vary with local protocols. As far as the
frequency of mammography is concerned, the Associa-
tion refers to the guidelines from the Royal College of
Radiologists which suggest 1- to 2-year intervals for up
to 10 years [23].
The 1998 clinical practice guidelines for the care of
BC from the Canadian Steering Committee [24], as well
as the 2005 guideline update [25], recommend that
mammography and clinical breast examination be more
frequent in the first few years and be performed indefi-
nitely at approximately 1-year intervals, although the
frequency may be adjusted according to individual
patient’s needs.
The 2006 update of the American Society of Clinical
Oncology guidelines recommend that all patients have a
careful history and physical examination every 3 to 6
months for the first 3 years, every 6 to 12 months for
years 4 and 5, and annually thereafter, and that a mam-
mogram be obtained at least 6 months after completion
of radiation therapy and every year thereafter [26]. It is
of note that no advice is given regarding patient dis-
charge to primary care, whereas previous guidelines of
1999 suggested that this should occur after 10 years
[12].
Finally, the European guidelines for mammography
screening recommend that screen-detected BC patients
have annual mammography [27] or periodical (not
otherwise specified) physical examination and mammo-
graphy [28]. In the section dedicated to annual surgical
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should be obtained and should have a technical quality
equivalent to those provided in the organised screening
programme. One could suggest that follow-up mammo-
grams of exactly the same quality as screening mammo-
grams can easily be found in screening centres.
Unfortunately, the text does not address where follow-
up mammography should be performed nor for how
long. However, in the section that deals with the defini-
tion of the population eligible for screening [30], it
reads that patients with previous BC (probably including
both screen-detected and prevalent BC patients) “ ...
may ...” be excluded from the programme. In other
words, and contrary to a widespread belief, the exclusion
of BC survivors from organised screening programmes is
presented as an option, not a necessity.
A Table in the Additional file 1 gives a summary of
the above surveillance guidelines.
One key point should be noted here. Most guidelines
place emphasis on providing frequent mammography
and clinical examination in the first 3 to 5 years after
diagnosis, and suggest that follow-up may be less fre-
quent or even terminated thereafter [12,18]. This is not
in accordance with the temporal pattern of the risk of
relapse. The pooled incidence of true local recurrence,
new BC in other areas of the ipsilateral breast, and new
contralateral BC is constant for at least 15 years [11,12].
By implication, if any breast surveillance is to be offered,
t h e r ei sn oo b v i o u sr e a s o nw h yi ts h o u l db em a d el e s s
frequent or even discontinued after a few years [18].
Current guidelines seem to be based on the assumption
that there exists an acute high-risk phase of follow-up.
In fact, this is only the case for the detection of scar
recurrences and distant metastases. It clearly appears
that most current guidelines are influenced, if not dic-
tated, by surgical and oncological priorities. By implica-
tion, they have limited or no relevance in terms of long-
term surveillance for the early detection of new ispilat-
eral and contralateral diseases.
This explains why most guidelines pay so much atten-
tion to the frequency of follow-up mammography and
so little to the complementary question of which health
setting is most appropriate. The option of providing
mammographic surveillance through organised screen-
ing programmes is simply not taken into consideration.
Surveillance practices in organised screening programmes
The inconsistency of practice guidelines, their emphasis
on the early post-treatment phase, and their ambiguity
and omissions are among the major reasons why BC
survivors are permanently or temporarily or partially
excluded from many - but not all - organised screening
programmes worldwide. It is important to note that
there is also a lack of consistency and clarity in policies
and procedures within the same countries.
In 1999, a survey of organised screening programmes
and mammography registries in 25 member countries of
the International Breast Cancer Screening Network was
performed. The objective was to determine what specific
data relating to screening monitoring were collected.
Information on whether women attending screening had
a history of BC was available from 15 countries. Most of
the national representatives of these countries stated
that women with a history of BC were specifically not
invited to screening [31].
In Sweden, for example, women who ask to be
excluded and women with previous BC are not invited,
and this is also the case for women with newly diag-
nosed, screen-detected cancer [32]. In Poland [33] and
Hungary [34], non-eligible women are defined as those
who have undergone surgical treatment for BC. In Swit-
zerland, gynaecologists and radiologists have agreed that
BC survivors need closer medical follow-up outside
organised screening programmes [35]. In Canada, the
target population at the national level is defined as
asymptomatic women aged 50-69 years with no prior
diagnosis of BC [36]. Recently, some provincial pro-
grammes have started to include BC survivors. These
women, however, are excludedf r o mr o u t i n es t a t i s t i c a l
reports for the first 5 years after diagnosis [37].
The Italian Group for Mammography Screening
guidelines do not establish a management standard for
women with a history of BC. However, they state that
only patients who are known with certainty to be fol-
lowed-up in the clinical setting can be excluded from an
organised screening programme, and that the exclusion
criteria should be clearly defined during the planning
phase [38]. As the planning and implementation of
screening are decentralized to the health care district
level, approaches differ in many respects [39-41]. In gen-
eral, BC survivors are indefinitely excluded. In situations
where identifying patients is impossible or impractical,
the invitation letter asks th e mt oi n f o r mt h es c r e e n i n g
service of their status, with exclusion occurring post-
hoc. In the health care district of Rome, those patients
who are being followed-up clinically are asked to send a
signed declaration to the screening service in which they
state their willingness to be excluded [42].
There are important organised programmes that use
different, if not opposite, approaches. For example, it is
not the policy of the United Kingdom NHS Breast
Screening Programme to exclude BC survivors. The
only women who are discontinued from the programme
are those with bilateral mastectomy, those who are con-
sidered by general practitioners to be medically unsuita-
ble due to terminal illness, and those who have
explicitly asked not to be invited. In all other circum-
stances, women have the opportunity of making an
informed choice about whether or not to accept a
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made [43]. The United Kingdom Society of Radiogra-
phers has suggested that patients with a recent history
might be followed-up outside the programme [44].
In Denmark, all women aged between 50 and 69 years
at the start of an invitation round are invited to screen-
ing unless they have specifically asked to be excluded
[45].
In Australia, the national mammography screening
programme selects women on the basis of age alone
(50-69 years) because “...The basis on which women are
eligible for screening must be clear and unequivocal“.O n
the website of the BreastScreen Australia programme, it
also reads that “Generally there is no dispute about a
women’s age...” and that “A n yp o l i c yi so n l ye f f e c t i v ei fi t
is able to be implemented“ [46]. This is obvious, but so
often forgotten.
The screening management of BC survivors is not a
binary option, i.e. exclusion or inclusion. It must be
borne in mind that organised screening programmes
no longer have a static design. It may happen that BC
survivors are systematically invited and managed with
non-standard procedures. One of these is the so-called
early or short-interval rescreen, an opportunity that
may be extended to inadvertently invited BC survivors
(when their status is unknown to the service). Early
rescreen may be used for several other conditions
including poor technical quality of mammograms,
high levels of mammographic breast density, hormone
replacement therapy use, and family history of BC
[47-49]. Where and with what frequency early
rescreen is practiced, however, is hard to establish.
Information is sparse. In Australia, the reasons for
offering screening more often than every 2 years
include a previous diagnosis of in situ carcinoma [50].
In northern Italy, BC survivors inadvertently invited
are among the 0.6% of total screening participants
who are placed on early rescreen [49]. A survey of
NHS mammography screening centres [47] showed
that 1.1% of total screening participants underwent
early rescreen and that 21% of these were made up of
BC survivors. In Canada, the total estimated rate of
early rescreen is above 10% [37].
Another hybrid model of BC survivor management,
which combines screening with a clinical service, has
been developed in the health care district of Rome.
Apart from some exceptions, all women receive a perso-
nal invitation to participate in the organised screening
programme. BC patients who are not followed-up else-
where are asked to contact the screening centre to
arrange a follow-up visit that is equivalent to an assess-
ment for a positive mammography result, after which
they are referred for specialist oncology consultation
[42].
These are only a few examples of the solutions that
have been adopted for the provision of mammographic
surveillance of BC survivors. Given the fact that orga-
nised screening activities are highly decentralised in
most countries, it can be assumed that the way in which
BC survivors are managed varies to a far greater extent
than is suggested by the information available.
Surveillance practices in the clinical setting
Variability in approaches to breast surveillance of BC
survivors is not confined to organised screening, but is
also observed in the clinical setting [20]. A survey of a
random sample of symptomatic breast imaging units in
England documented an impressive disparity of proto-
cols [51]. The same patient, depending on her place of
residence, can be discharged to the national screening
programme immediately after treatment or have an
annual mammography for 10 years, although most units
recommend a 5-year duration of follow-up. In certain
units, the schedule for patients treated with breast con-
serving surgery is based on a different frequency of
mammography for the ipsilateral and contralateral
breast. Such a scheme has a high risk of being misun-
derstood by patients, as suggested by the fact that they
are more aware of the risk of ipsilateral relapse [18], and
of being mismanaged by the follow-up service.
In England and elsewhere, the degree of within- and
between-centre variation inf o l l o w - u ps t r a t e g i e sh a s
probably increased over time because of a qualitative
change in the service workload. In all populations tar-
geted by screening, the growth in the number of BC
patients to be followed-up is associated with a broaden-
ing range of clinical situations due to the fact that the
presence of screen-detected cancers amplifies the het-
erogeneity of biological characteristics of the disease
[52]. This, in turn, may widen the spectrum of proposed
follow-up schedules. Some breast imaging units use one
or more tumour-related risk factors for local recurrence
to modulate the duration and frequency of examinations
[51].
Attendance to mammographic surveillance
Uncertainties about the optimal setting for mammo-
graphic surveillance, together with the variability of
practices, may create confusion among BC patients
invited to screening or referred to the clinical setting. In
turn, this may adversely affect their compliance, espe-
cially in the medium-long term [2].
To the author’s knowledge, there are no data on the
proportion of BC survivors excluded from an organised
screening programme who present for mammographic
follow-up in the clinical setting. The only available stu-
dies on attendance of BC patients at clinical breast ima-
ging units are from the United States, where
approximately 80-85% patients with early BC return for
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[56,57] after treatment. Attendance at annual mammo-
graphic follow-up, however, decreases with unexpected
rapidity to approximately 65% in the fourth or fifth year
[53,55]. Such a level is acceptable only for the general
population of women at average risk of disease. Unfor-
tunately, but in line with guidelines that recommend a
decreasing intensity of follow-up over time, there are no
data on the degree of attendance over longer time
periods.
It is curious to note that one of the suggested explana-
tions for mammography underuse among BC survivors
is that their concern about cancer recurrence is greater
in the first years after treatment [58]. Whilst this inter-
pretation is probably correct, it must be acknowledged
that the same concerns are apparently shared by the
experts who developed the surveillance guidelines and
by those who assessed their implementation.
Data are also lacking on the response rate of BC
patients invited to organised screening at both short and
standard interscreening intervals. A single, large study
from the United Kingdom reviewed a cohort of BC sur-
vivors after 5 or more years of survival, i.e. after their
return to the organised screening programme [59].
These women were 22% less likely to accept invitation
than non-cancer controls. It is surprising that so little is
known about mammography use by BC survivors in
countries other than the United States [60].
A similar paucity of data extends to the health out-
comes of these patients. The exclusion of BC survivors
from organised screening programmes is based on the
assumption that they will have an advantage from
undergoing clinical mammography in the sense that a
second BC would theoretically be detected at an earlier
stage. In actual fact, the only available tumour stage
data are from selected clinical series [17]. Population-
based studies are precluded by the fact that general can-
cer registries report new ipsilateral and contralateral pri-
maries, but not recurrent cancers.
Arguments for and against different settings for
mammographic surveillance
There are several other considerations that may contri-
bute to the rationale behind the decision-making on the
provision of mammographic surveillance for BC
survivors.
Clinical control over mammography
Oncologists and other hospital specialists tend to retain
direct control over the clinical investigations that are
indicated to detect a cancer recurrence, and this is also
the case for follow-up mammography. As intensive
screening for asymptomatic metastatic relapse is not
recommended because it does not improve survival or
quality of life [10,61], the hospital follow-up of BC
patients appears to be targeted at the following objec-
tives: (1) to monitor ongoing adjuvant treatment and
side-effects; (2) to review the patients who are partici-
pating in clinical trials; (3) t og i v ei n f o r m a t i o no ng e n -
eral health, diet and exercise; (4) to identify and treat
psychosocial problems; (5) to manage comorbidity; (6)
to detect symptomatic true ipsilateral breast recurrences
and axillary recurrences by clinical examination; and (7)
to detect new asymptomatic cancers in both the treated
and the contralateral breast using mammography
[18,20,62].
Objectives #1 to 6 require a patient-physician interac-
tion, which can take place in a hospital outpatient
oncology or surgery clinic or, after the transfer of
responsibility, in the primary care setting or elsewhere
in the clinical health care environment [62]. This is not
the case for the mammographic detection of a new BC.
Oncologists, surgeons, and primary care physicians can
only prescribe, but not perform, mammography. The
only control that they can exercise over it is over its fre-
quency. In other words, the only reason for which they
may prefer that BC survivors be followed-up in a clinical
radiology setting is that the frequency of mammography
can be higher than in a screening setting. However, it is
a fact that the provision of short-interval mammography
for high-risk women is also relatively common in orga-
nized screening programmes [37,47-49].
Patients’ views about mammographic surveillance
BC patients’ views should be given closer attention when
planning post-treatment follow-up. A systematic review
of qualitative studies reporting on patients’ views and
preferences about follow-up for any type of cancer has
shown that they attach importance to the regularity of
follow-up appointments, expertise of specialists, rapid
access to tests, and continuity of care and information
[63]. There is no published information about BC survi-
vors’ attitudes towards the different options available for
mammographic surveillance.
Limitations of cancer registration
The exclusion of women with BC from an organised
screening programme involves the identification of all
prevalent as well as incident BC patients. The latter
should also be promptly notified to the screening ser-
vice. This is impossible to achieve in several countries
and regional areas due to the absence of cancer registra-
tion or limitations in geographic coverage or time cover-
age. Additional problems may be caused by the latency
time of cancer registries, legal restrictions of access to
their files, and poor quality of record linkage
procedures.
Many mammographic surveillance protocols recom-
mend that BC patients be returned to normal screening
after some years (generally 5) of exclusion [51]. It is
interesting to note that the latency time of cancer
Bucchi BMC Health Services Research 2011, 11:249
http://www.biomedcentral.com/1472-6963/11/249
Page 6 of 13registries accounts for most, if not all, of this period.
This means that during the latency time only screen-
detected cancer patients are known to the screening ser-
vices and can be excluded from invitation. The rest of
incident cancer patients (a subgroup of the same order
of magnitude) cannot be excluded until the latency time
has expired. This confirms that current mammographic
surveillance protocols are designed for the physician-
patient setting, not for population-based screening
programmes.
Inequalities in patient management
The health inequalities facing BC patients during post-
treatment breast surveillance are not adequately per-
ceived. The limitations of cancer registration translate
into a mixed practice of both exclusions and inclusions
from organised screening, i.e. different types of manage-
ment being adopted by the same service for patients
with the same condition. This is unacceptable in princi-
ple, may negatively affect the image of the screening
programme, and may be associated with medico-legal
hazards. BC patients excluded from organised screening
programmes are subject to further inequalities when
they present for mammographic follow-up in the clinical
setting. As pointed out above, the current multiplicity of
different recommendations results in an extreme diver-
sity of protocols in use [51].
Rate of abnormal mammograms
It has been suggested that excluding BC survivors from
organised screening programmes would be justified if
their rate of abnormal mammograms requiring subse-
quent recall for diagnostic work-up was significantly
greater than that of the general target population. If this
was the case, the level of inconvenience for these
women would be excessive and immediate evaluation in
a diagnostic setting would appear more appropriate [1].
Theoretically, patients treated with conserving surgery
and radiotherapy are expected to have an increased pre-
v a l e n c eo fm a m m o g r a p h i ca bnormalities because they
have an altered breast architecture which changes over
time and causes difficulties in radiological interpretation
[51]. To what extent this actually affects the recall rate
for diagnostic assessment, however, cannot be estab-
lished from the little data available [1,64]. At present, it
is premature to recommend that BC survivors be fol-
lowed-up in the clinical setting based only on the pre-
sumed increase in abnormal mammograms. Incidentally,
it should be noted that this paucity of data extends to
all performance measures of mammographic surveil-
lance including cancer detection rate, positive predictive
value, and interval cancer rate [10].
Biases in screening monitoring
Despite the lack of information, it should be taken into
account that including BC survivors in the target popu-
lation may influence the results of an organised
screening programme. In particular, this may be the
case for indicators related to the prevalence of mammo-
graphic breast abnormalities and of BC. The biasing
effect of the presence of BC survivors could be consid-
ered, at least in part, a disadvantage from a quality mon-
itoring point of view, e.g. in cross-national and
international comparisons of screening results. This pro-
blem, however, can be overcome by excluding women
with a personal history of BC from data reports and
analyses. There is no “statistical” need to exclude them
from screening. This approach, which has been pro-
posed by the European guidelines for mammography
screening [30], is currently being used in some pro-
vinces in Canada where BC survivors are invited to
screening but withdrawn from data reporting for the
first 5 years after their diagnosis [37].
Cost considerations
Economic evaluations have concentrated on comparing
follow-up, including mammographic follow-up, of BC in
primary care versus secondary or specialist care [62,65].
The provision of follow-up mammography in the
screening setting is not considered an option worthy of
cost-effectiveness and cost-minimisation analysis.
Current challenges
Important changes are either underway, in preparation
or at the research stage in procedures for BC screening
and post-treatment management of women with BC.
These developments have a potential to affect the way
in which the problems with mammographic surveillance
of BC survivors are perceived and treated.
BC survivorship research
Preventive health care needs of BC survivors are a speci-
fic topic of BC survivorship research. The term cancer
survivorship encompasses the many physical, psychoso-
cial, and economic sequelae of cancer diagnosis and
treatment as well as the related short- and long-term
needs of the patients. Cancer survivorship research aims
at developing an evidence base for optimal follow-up
care practices using a multidisciplinary approach.
The most important objective remains the achieve-
ment of a higher level of evidence of effectiveness of
mammographic surveillance of BC survivors in reducing
mortality. Other major issues to be addressed include
the effectiveness of surveillance as specifically provided
in the screening setting [10] and the relative effective-
ness associated with different time intervals. It is clear
that studies aimed at evaluating these potential benefits
will be impossible to conduct in countries and regional
areas where BC survivors are not eligible for organised
screening programmes.
Obtaining access to appropriate care services through
delivery systems that are complementary and not dupli-
cative [66] is a primary area of improvement. From this
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schemes between specialists and primary care physi-
cians, which includes formalization of the transfer of
care [53,67,68], is considered insufficient to substantially
improve patient management [66]. The coordination
strategy should extend to a larger number of health ser-
vices. Numerous models for delivering survivorship care
have been proposed [63,69]. The complicated question
of how mammographic surveillance could be incorpo-
rated into these comprehensive care planning processes
is among the areas of BC survivorship where more
research is needed.
Ap a t i e n t ’s family members are considered part of the
survivorship experience. Indeed, post-treatment care is
increasingly viewed as a spectrum of interventions
aimed at improving the health and lives of cancer survi-
vors and their families [66]. On the one hand, the well-
being of the millions of family members of cancer survi-
vors, many of whom are themselves at high risk for can-
cer, is a matter of increasing concern. On the other
hand, it is now recognised that household members
h a v ear o l ei ns u r v i v o r s ’ health-related outcomes. From
this perspective, there is an objective interrelationship
between the management of the personal high-risk con-
dition of a BC patient and the management of the high-
risk condition that affects her female family members. It
might be worth studying whether there could be some
benefit from coordinating these two parallel surveillance
activities.
Socio-economic factors of adherence to mammographic
surveillance
The expansion of BC survivorship research will help us
to understand and control the effects of socio-eco-
nomic factors on patient attendance at post-treatment
mammographic surveillance. The observed underuse of
mammography is mostly related to clinical and medical
factors such as advanced patient age, comorbidities,
late disease stage of primary cancer, insufficient team-
work between oncology specialists and primary care
physicians [67,68], and inadequate instructions on pre-
ventive care. Studies on the underuse of screening
mammography in the general population and on fol-
low-up failures after a positive screening result indicate
the need to investigate the role of socio-economic fac-
tors in explaining the degree of patients’ adherence to
recommendations.
Risk-based surveillance protocols
The feasibility, cost-effectiveness, and potential benefits
of different risk-based protocols for mammographic fol-
low-up in the clinical setting are important areas of clin-
ical research. Efficient protocols could facilitate the
discharge of low-risk patients to the organised screening
activity. Many tumour-related risk factors for local
recurrence have been identified which could be used to
modulate the duration and frequency of mammographic
follow-up. A small number of breast imaging units are
already using one or more of these factors to schedule
appointments [51].
Further research in the form of a controlled trial is
necessary to determine optimal surveillance regimens. In
this respect, however, a problem exists in that obtaining
ethical approval may be difficult. Although there is no
evidence to support current guideline recommendations
for annual mammography, it could be deemed unethical
to randomly assign patients to receive a lower level of
surveillance [51].
Risk-tailored screening
Inviting BC survivors to participate in an organised
screening programme inherently conveys the innovative
and controversial concept of tailoring the screening pro-
cedure to the personal risk of disease. This would
involve the implementation of risk assessment in screen-
ing facilities [70] and major changes in service delivery
arrangements. Risk-tailored screening would provide an
opportunity to both increase the impact on mortality
and reduce the human and economic cost of screening
[71]. For example, the frequency of screening in women
who are assessed as being at lower risk levels could be
reduced. At present, however, we still need to learn how
to combine the many known risk factors for BC [71,72].
Moreover, risk-tailored screening will need to be evalu-
ated in prospective trials, although it has been proposed
that surrogate indicators of effectiveness (such as
tumour stage at diagnosis) be used [71].
Such a perspective warrants a research effort. In a par-
allel line of investigation, it has been hypothesised that
quantifying both the individual risk of multiple BC and
the familial risk, as well as their interactions, in popula-
tions exposed for extended periods to organised screen-
ing programmes could be helpful to identify optimal
preventive strategies [13,73].
Screening after age 69 years
In the Netherlands women are routinely invited to orga-
nised screening programmes up to 75 years of age, in
France and Sweden up to 74 years. The extension to 73
and 74 years is being planned in the United Kingdom
and some Italian administrative regions, respectively.
Recommendations on how long to continue screening
mammography on a spontaneous basis are also expected
to evolve.
Raising the upper age limit for organised screening
may influence the mammographic surveillance of BC
survivors in two ways. First, assuming that they are not
invited, it is reasonable to expect that they will be fol-
lowed-up in the clinical setting at least until the age of
74. A survey of breast imaging units in England has
shown that variability in the duration of mammographic
follow-up is especially pronounced for patients aged 70
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cessation at 69 years probably reflects the most common
upper age limit for organised screening, although the
effectiveness of mammography for women aged up to
74 years has been demonstrated in several randomized
trials.
Second, the inclusion of women aged 70 years or older
in organised screening programmes may facilitate the
inclusion of BC survivors themselves. An Australian
modelling study aimed at estimating the costs and bene-
fits of continuing screening mammography after 69
years of age concluded that a benefit is more likely in
women who are at high risk of death from BC and
those at low risk of death from other causes [74]. In the
event the upper age limit for screening is raised, BC sur-
vivors should be considered candidates for invitation,
provided that primary care physicians select those who
are eligible on the basis of evaluation of life expectancy
and severity of comorbidities.
Consultation with primary care physicians is impor-
tant for all elderly women, with or without a personal
history of BC. Both populations need to be provided
with guidance on mammography, regardless of whether
they will be screened in the clinical setting or in an
organised screening programme. In the latter case, how-
ever, a subtle change in the design of screening inevita-
bly occurs. As the participation of elderly women is
dependent on an assessment of life expectancy per-
formed by primary care physicians, it can be said that
they are screened for eligibility before undergoing
screening for BC. This two-stage procedure is equivalent
to a selective screening for women who have low com-
peting risks of death and a potential for benefit from
mammography.
Breast units
Medical organisations are increasingly recommending
that breast diseases be cared for by specialists working
as a team in multidisciplinary breast units. The section
of the European guidelines for mammography screening
which defines the ideal requirements for breast units
introduces a new concept of the interrelationship
between population-based screening activities and clini-
cal breast care services [75]. It is stated that organised
screening programmes should be based within a breast
unit, and that any radiologist who reads clinical mam-
mograms should participate in the organised screening
programme in those countries in which this is
established.
This model of provision of breast care, in which the
separation of screening from clinical breast services is
no longer straightforward, may also have implications
for breast surveillance of BC survivors. European guide-
lines recommend that such patients be followed-up in a
breast unit under the direct supervision of one of the
surgeons, and that any necessary imaging be carried out
at the same visit. In line with these criteria, but also
with the aim of optimising the use of resources, it could
be proposed that patients be followed-up in the clinical
setting of the breast unit but using the personal call/
recall service of the organised screening programme.
This would improve attendance rates and would facili-
tate the subsequent return to the programme.
The process of the establishment of breast units in
Europe is in its initial stages, and their organisation var-
ies greatly between countries [76]. It is possible that a
variety of models of cooperation between screening and
clinical services will be proposed in the future.
BC registration
W h e r et h e r ei sap o l i c yt oe x c l u d eB Cs u r v i v o r sf r o m
organised screening programmes, such individuals need
to be systematically identified. In turn, this makes it
necessary to improve the spatial and temporal coverage
of cancer registration.
The introduction of a screening programme provides
the motivation for expanding a general cancer registry
or for implementing a special, screening-oriented BC
registry, although optimal results are impossible [49].
Hospital discharge records, medical insurance claim
files, treatment records, pathology report files, and noti-
fications from primary care physicians are potential
alternatives to cancer registry data when these are not
(or not readily) available. However, data from hospital
discharge records and medical insurance claim files are
often very complex and require training and support.
The frequent lack of a unique universal identifier causes
additional difficulties because the quality of electronic
record linkage procedures is always less than perfect.
Rapid case ascertainment procedures can shorten, but
not eliminate, the latency time.
Possible interim solutions
Ongoing and potential developments in the area of BC
cancer screening and care might offer solutions to pro-
blems arising from current patterns of breast surveil-
lance of BC survivors. However, this is not expected to
happen in the near future. In the interim, there are
some practical corrective measures that could be
implemented.
Primary care physicians
Many studies on the provision of mammographic sur-
veillance have concluded that the coordination between
the services involved needs to be improved. To this end,
the first step is to better define the role and responsibil-
ities of primary care physicians [67,68]. In health care
systems where these are clear, such as in the United
Kingdom, cancer survivors receive preventive care at
similar levels to the non-cancer population. Where the
role of primary care physicians is less clearly defined,
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contact with surgeons and oncologists after discontinua-
tion of hospital follow-up [59]. Data from the United
Kingdom have confirmed that primary care physicians
order follow-up mammograms more frequently than
hospital specialists [65]. Studies from the United States,
conversely, have led to the hypothesis that mammogra-
phy rates decrease rapidly after treatment because pri-
mary care physicians have insufficient knowledge of the
benefit of surveillance [53].
Local flow charts
Another option to improve the coordination of care for
BC survivors, including breast surveillance, would be to
introduce practice guidelines and, more specifically, flow
charts on a local basis. These would be designed to
assist all health care providers in the implementation of
follow-up, would illustrate the crucial points in patient
management, and would eliminate redundant or inap-
propriate actions.
The implementation of a population-based screening
programme, which increases the number of BC survi-
vors and creates new inequalities, offers a unique oppor-
tunity for local public health authorities to promote the
development and adoption of flow charts for mammo-
graphic surveillance. As research evidence of the effec-
tiveness of different protocols is lacking, flow charts
should be based on empirical experience. A realistic
consensus between practicing physicians at the commu-
nity level, with the identification of distinct roles for the
screening service and clinical practitioners, would be
much easier to achieve than a large-scale consensus
between experts. Moreover, a local approach would
offer the advantage of greater flexibility in the applica-
tion of health regulations from higher levels of
government.
Screen-detected patients
In a population targeted by an organised screening pro-
gramme, screen-detected patients account for approxi-
mately half of BC incidence. By definition, they are
known to screening centres and can immediately be
excluded from subsequent screening rounds. It seems
more reasonable, however, for the mammographic fol-
low-up of this subset of BC patients to take place in the
same setting in which they were diagnosed. For exam-
ple, accreditation standards recently introduced in an
administrative region of northern Italy stipulate (1) that
all organised screening centres should offer annual fol-
low-up mammography to patients with screen-detected
BC, (2) that these should receive personal ad-hoc invita-
tion letters, and (3) that their mammographic follow-up
status should be checked at regular intervals by the
same staff who check whether women with a positive
basic screening result have undergone diagnostic assess-
ment [77].
It is doubtful whether this policy could be implemen-
ted, in its entirety, in other health systems and under
different health regulations, especially with respect to
the status and role of primary care physicians. However,
this model illustrates the growing idea that breast cancer
screening should comprise multiple surveillance proce-
dures aimed at subsets of the population with different
risk levels.
Recording of screening data
The proportion of BC patients who participate in orga-
nised screening programmes, either because of incom-
p l e t ee x c l u s i o no rb e c a u s et h e ya r ei n v i t e db yd e s i g n ,i s
probably much greater than is commonly assumed.
However, there are no reliable data to confirm this. The
status of cancer survivors is seldom recorded in mam-
mography databases, and there may also be some confu-
sion as to when to enter these women as clinical cases
and when to include them again in the basic screening
population. The return to basic screening has been
called “a grey area” [47], which highlights the need for
guidelines for the management and classification of
patients.
In Europe, there is increasing awareness that the func-
tions of the computer systems used in screening activ-
ities need to be improved. This also applies to
completeness and consistency of the recorded items
[78]. Until the hypothesis of risk-tailored screening has
been prospectively studied with ad-hoc designs, it would
be useful to have a code indicative of patient status to
be entered in service databases. This would enable us to
evaluate the attendance rate, the rate of abnormal mam-
mograms, and the detection rate of second breast cancer
among BC survivors [17].
A collaboration scheme between primary care physicians
and organised screening programmes
Until ongoing and expected modifications in BC can-
cer screening and care provide substantial solutions
to problems with breast surveillance of BC survivors,
it is the author’s opinion that many shortcomings
could at least be mitigated by the adoption of an
organisational model in which: (1) the primary care
physician retains (or regains) full accountability for
the follow-up care of BC patient; (2) the whole target
population is invited to the organised screening pro-
gramme; (3) the primary care physician advises the
BC patient to decline the invitation to screening in
the event of a recent or imminent clinical mammo-
graphy; (4) otherwise, and after assessment of life
expectancy and competing risks, he encourages the
patient to participate; (5) after her first screening
mammography, the patient is re-invited annually until
the standard age of cessation; and (6) the mammogra-
phy report is forwarded to the primary care physician,
who supervises follow-up.
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the United Kingdom NHS Breast Screening Programme.
Its rationale is that: (1) it leaves unchanged the existing
information flows to cancer registries; (2) it avoids
inequalities in the public provision of mammography
service; (3) it is in keeping with the view that patients
who are not known with certainty to be followed-up in
the clinical setting cannot be excluded from an orga-
nised screening programme; (4) it extends the provision
of a fail-safe mechanism against discontinuation of
mammographic surveillance; and (5) it decreases the
likelihood of over-investigation.
Summary
BC survivors are still a small but no longer negligible
minority of women in the age range targeted by orga-
nised mammography screening programmes. Due to
their increasing numbers, the problem of determining
the most appropriate setting in which to carry out their
mammographic surveillance can no longer be ignored.
This article, that is based on an international compari-
son of policies and practices for such women, docu-
ments a poor level of evidence-based information, an
absolute lack of consistency and clarity, and several
points of irrationality. Breast surveillance of BC survi-
vors, like other needs of this growing population, has
not been addressed in a satisfactory manner and must
be given a higher rank in the cancer survivorship
research agenda.
The main aspects of the problem include: weak evi-
dence that mammographic surveillance decreases mor-
tality; a lack of objective evidence in favour of one
setting or the other; a lack of evidence-based guidelines
for the frequency and duration of surveillance; a dispro-
portionate emphasis being placed on the first few years
after treatment, probably dictated by surgical and onco-
logical priorities; a variety of screening policies, as these
women are permanently, temporarily or partially
excluded from many - but not all - organised screening
programmes worldwide; an even greater disparity of fol-
low-up protocols being used in the clinical setting; a
p a u c i t yo fd a t ao nc o m p l i a n c et om a m m o g r a p h i cs u r -
veillance in both settings; and difficulty in coordinating
the roles of health care providers. The problem of
where and how to provide mammographic surveillance
for BC survivors is situated at the crossroads of numer-
ous different specialist areas of BC control. A solution
w i l lb ef o u n do n l yb ye x p a n d i n gt h ec o n v e n t i o n a lt h e o -
retical boundaries of secondary prevention of BC.
Following this line of reasoning, it is probable that
novel approaches to coping with mammographic sur-
veillance for BC survivors will emerge from some
important modifications in the conventional screening
procedure that are underway, such as the early rescreen
practice and the implementation of breast units, or are
still undergoing research, such as the hypothesis of risk-
tailored screening. Taken as a whole, these develop-
ments are directed towards a partial integration, at the
functional or structural level, between BC screening and
clinical breast services. This would necessarily involve
modifications of the traditional screening rationale, with
an adaptation to meet the diversified breast care needs
of women.
Such a complexity constitutes a call to action for
health policy-makers, screening authorities and specia-
lists to eliminate the barriers to effective research into
innovative models for breast surveillance of BC survi-
vors. Until these models are developed, there are techni-
cal solutions in patient flow and care coordination that
can alleviate the most serious shortcomings. A collective
commitment to a comprehensive approach to these pro-
blems is needed.
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